{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:04:11Z","timestamp":1790244251542,"version":"4.1.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T00:00:00Z","timestamp":1540425600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007393","name":"Association Fran\u00e7aise contre les Myopathies","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007393","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011272","name":"FP7 Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.02399","type":"journal-article","created":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T12:58:38Z","timestamp":1540472318000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["A Natural Variant of the Signaling Molecule Vav1 Enhances Susceptibility to Myasthenia Gravis and Influences the T Cell Receptor Repertoire"],"prefix":"10.3389","volume":"9","author":[{"given":"Isabelle","family":"Bernard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Sacquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Kassem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Benamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Colacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myl\u00e8ne","family":"Gador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corine","family":"P\u00e9rals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Fazilleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelhadi","family":"Saoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,10,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/nri916","article-title":"Unravelling the pathogenesis of myasthenia gravis","volume":"2","author":"Vincent","year":"2002","journal-title":"Nat Rev Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jaut.2014.01.003","article-title":"Diagnostic and clinical classification of autoimmune myasthenia gravis","author":"Berrih-Aknin","year":"2014","journal-title":"J Autoimmun."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12688\/f1000research.8206.1","article-title":"Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms","volume":"5","author":"Phillips","year":"2016","journal-title":"F1000Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e108327","DOI":"10.1371\/journal.pone.0108327","article-title":"Direct proof of the in vivo pathogenic role of the AChR autoantibodies from myasthenia gravis patients","volume":"9","author":"Kordas","year":"2014","journal-title":"PLoS ONE"},{"key":"B5","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00415-011-6194-7","article-title":"Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis","volume":"259","author":"Pevzner","year":"2012","journal-title":"J Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1001\/archneurol.2011.2393","article-title":"Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis","volume":"69","author":"Zhang","year":"2012","journal-title":"Arch Neurol."},{"key":"B8","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1126\/science.180.4088.871","article-title":"Autoimmune response to acetylcholine receptor","volume":"180","author":"Patrick","year":"1973","journal-title":"Science"},{"key":"B9","doi-asserted-by":"publisher","first-page":"5050","DOI":"10.4049\/jimmunol.175.8.5050","article-title":"Estrogen enhances susceptibility to experimental autoimmune myasthenia gravis by promoting type 1-polarized immune responses","volume":"175","author":"Delpy","year":"2005","journal-title":"J Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1196\/annals.1405.027","article-title":"Genetic factors in autoimmune myasthenia gravis","volume":"1132","author":"Giraud","year":"2008","journal-title":"Ann N Y Acad Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1001\/jamaneurol.2014.4103","article-title":"A genome-wide association study of myasthenia gravis","volume":"72","author":"Renton","year":"2015","journal-title":"JAMA Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/ana.20751","article-title":"Association of the PTPN22*R620W polymorphism with autoimmune myasthenia gravis","volume":"59","author":"Vandiedonck","year":"2006","journal-title":"Ann Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.humimm.2009.04.027","article-title":"The autoimmunity-related polymorphism PTPN22 1858C\/T is associated with anti-titin antibody-positive myasthenia gravis","volume":"70","author":"Greve","year":"2009","journal-title":"Hum Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/ana.23691","article-title":"Risk for myasthenia gravis maps to a (151) Pro\u2013>Ala change in TNIP1 and to human leukocyte antigen-B*08","volume":"72","author":"Gregersen","year":"2012","journal-title":"Ann Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/sj.gene.6363816","article-title":"CDS1 and promoter single nucleotide polymorphisms of the CTLA-4 gene in human myasthenia gravis","volume":"3","author":"Wang","year":"2002","journal-title":"Genes Immun."},{"key":"B16","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/ana.20577","article-title":"A CTLA4high genotype is associated with myasthenia gravis in thymoma patients","volume":"58","author":"Chuang","year":"2005","journal-title":"Ann Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/acn3.51","article-title":"VAV1 and BAFF, via NFkappaB pathway, are genetic risk factors for myasthenia gravis","volume":"1","author":"Avidan","year":"2014","journal-title":"Ann Clin Transl Neurol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/374474a0","article-title":"Defective T-cell receptor signalling and positive selection of Vav-deficient CD4+ CD8+ thymocytes","volume":"374","author":"Fischer","year":"1995","journal-title":"Nature"},{"key":"B19","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/374467a0","article-title":"Defective antigen receptor-mediated proliferation of B and T cells in the absence of Vav","volume":"374","author":"Tarakhovsky","year":"1995","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/374470a0","article-title":"Defective signalling through the T- and B-cell antigen receptors in lymphoid cells lacking the vav proto-oncogene","volume":"374","author":"Zhang","year":"1995","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1074-7613(00)80367-2","article-title":"A requirement for the Rho-family GTP exchange factor Vav in positive and negative selection of thymocytes","volume":"7","author":"Turner","year":"1997","journal-title":"Immunity"},{"key":"B22","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.coi.2005.04.003","article-title":"Vav-family proteins in T-cell signalling","volume":"17","author":"Tybulewicz","year":"2005","journal-title":"Curr Opin Immunol."},{"key":"B23","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S0960-9822(98)70224-6","article-title":"Vav is a regulator of cytoskeletal reorganization mediated by the T-cell receptor","volume":"8","author":"Fischer","year":"1998","journal-title":"Curr Biol."},{"key":"B24","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1073\/pnas.96.6.3035","article-title":"The Rho-family GTP exchange factor Vav is a critical transducer of T cell receptor signals to the calcium, ERK, and NF-kappaB pathways","volume":"96","author":"Costello","year":"1999","journal-title":"Proc Natl Acad Sci USA."},{"key":"B25","doi-asserted-by":"publisher","first-page":"ra83","DOI":"10.1126\/scisignal.2000420","article-title":"Function of the nucleotide exchange activity of vav1 in T cell development and activation","volume":"2","author":"Saveliev","year":"2009","journal-title":"Sci Signal."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e1006185","DOI":"10.1371\/journal.pgen.1006185","article-title":"A natural variant of the T cell receptor-signaling molecule Vav1 reduces both effector T cell functions and susceptibility to neuroinflammation","volume":"12","author":"Kassem","year":"2016","journal-title":"PLoS Genet."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1084\/jem.20102191","article-title":"The p","volume":"208","author":"Colacios","year":"2011","journal-title":"J Exp Med."},{"key":"B28","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/0076-6879(81)74031-X","article-title":"Production and assay of antibodies to acetylcholine receptors","volume":"74","author":"Lindstrom","year":"1981","journal-title":"Methods Enzymol."},{"key":"B29","doi-asserted-by":"crossref","first-page":"7189","DOI":"10.4049\/jimmunol.162.12.7189","article-title":"Experimental autoimmune myasthenia gravis may occur in the context of a polarized Th1- or Th2-type immune response in rats","volume":"162","author":"Saoudi","year":"1999","journal-title":"J Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/1521-4141(200101)31:1<225::AID-IMMU225>3.0.CO;2-0","article-title":"Disruption of the IL-1beta gene diminishes acetylcholine receptor-induced immune responses in a murine model of myasthenia gravis","volume":"31","author":"Huang","year":"2001","journal-title":"Eur J Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4049\/jimmunol.172.1.97","article-title":"The susceptibility to experimental myasthenia gravis of STAT6\u2212\/\u2212 and STAT4\u2212\/\u2212 BALB\/c mice suggests a pathogenic role of Th1 cells","volume":"172","author":"Wang","year":"2004","journal-title":"J Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1084\/jem.186.3.385","article-title":"Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice","volume":"186","author":"Balasa","year":"1997","journal-title":"J Exp Med."},{"key":"B33","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1002\/(SICI)1521-4141(199808)28:08<2487::AID-IMMU2487>3.0.CO;2-Y","article-title":"IL-12 is involved in the induction of experimental autoimmune myasthenia gravis, an antibody-mediated disease","volume":"28","author":"Moiola","year":"1998","journal-title":"Eur J Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/mus.22070","article-title":"Increased serum interleukin-17 levels in patients with myasthenia gravis","volume":"44","author":"Roche","year":"2011","journal-title":"Muscle Nerve"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1002\/eji.201445064","article-title":"IL-17-producing CD4(+) T cells contribute to the loss of B-cell tolerance in experimental autoimmune myasthenia gravis","volume":"45","author":"Schaffert","year":"2015","journal-title":"Eur J Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.4049\/jimmunol.1501339","article-title":"Autoreactive T cells from patients with myasthenia gravis are characterized by elevated IL-17, IFN-gamma, and GM-CSF and diminished IL-10 production","volume":"196","author":"Cao","year":"2016","journal-title":"J Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.cyto.2017.05.008","article-title":"Ablation of IL-17 expression moderates experimental autoimmune myasthenia gravis disease severity","volume":"96","author":"Aguilo-Seara","year":"2017","journal-title":"Cytokine"},{"key":"B38","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/imr.12032","article-title":"Early signaling events that underlie fate decisions of naive CD4(+) T cells toward distinct T-helper cell subsets","volume":"252","author":"Yamane","year":"2013","journal-title":"Immunol Rev."},{"key":"B39","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.it.2014.09.008","article-title":"TCR signal quantity and quality in CD4(+) T cell differentiation","volume":"35","author":"Tubo","year":"2014","journal-title":"Trends Immunol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.immuni.2014.06.003","article-title":"T-cell-receptor-dependent signal intensity dominantly controls CD4(+) T cell polarization in vivo","volume":"41","author":"van Panhuys","year":"2014","journal-title":"Immunity"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.4049\/jimmunol.170.5.2427","article-title":"Role of TCR-induced extracellular signal-regulated kinase activation in the regulation of early IL-4 expression in naive CD4(+) T cells","volume":"170","author":"Jorritsma","year":"2003","journal-title":"J Immunol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1084\/jem.20051304","article-title":"Independent roles for IL-2 and GATA-3 in stimulating naive CD4(+) T cells to generate a Th2-inducing cytokine environment","volume":"202","author":"Yamane","year":"2005","journal-title":"J Exp Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/ni1040","article-title":"Duration of TCR signaling controls CD4-CD8 lineage differentiation in vivo","volume":"5","author":"Liu","year":"2004","journal-title":"Nat Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"10ra21","DOI":"10.1126\/scitranslmed.3000278","article-title":"A role for VAV1 in experimental autoimmune encephalomyelitis and multiple sclerosis","volume":"1","author":"Jagodic","year":"2009","journal-title":"Sci Transl Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/gene.2016.49","article-title":"VAV1 regulates experimental autoimmune arthritis and is associated with anti-CCP negative rheumatoid arthritis","volume":"18","author":"Guerreiro-Cacais","year":"2017","journal-title":"Genes Immun."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02399\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T10:52:29Z","timestamp":1693997549000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02399\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,25]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2018.02399"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.02399","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,25]]},"article-number":"2399"}}